| Hervey Mac Madden, MD | |
|
3302 E Moore Ave, Searcy, AR 72143-4886 | |
| (501) 268-4181 | |
| (501) 268-5301 |
| Full Name | Hervey Mac Madden |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 3302 E Moore Ave, Searcy, Arkansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710017686 | NPI | - | NPPES |
| Entity Name | Preferred Family Healthcare, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649474206 PECOS PAC ID: 0244256246 Enrollment ID: O20051019000599 |
News Archive
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that East Tennessee Children's Hospital has selected ProVation® Order Sets, powered by UpToDate® Decision Support, to automate the creation, deployment and maintenance of order sets.
The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Consultant Urological Surgeon Martin Moody FRCS, to present case for safer surgery alongside Henry Schniewind of HAT in Val d'Isère during the medical conference, Doctors Updates.
Zhang and co-principal investigators Sheng Ding, PhD, from The Scripps Research Institute, and Thomas Reh, PhD from the University of Washington, received the highest possible scores for their proposal to investigate the regenerative potential of retinal cells. Their long-term goal is to restore visual function lost through diseases such as macular degeneration and retinitis pigmentosa.
Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hervey Mac Madden, MD 25 Gap Rd, Batesville, AR 72501-8679 Ph: (870) 793-8900 | Hervey Mac Madden, MD 3302 E Moore Ave, Searcy, AR 72143-4886 Ph: (501) 268-4181 |
News Archive
Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that East Tennessee Children's Hospital has selected ProVation® Order Sets, powered by UpToDate® Decision Support, to automate the creation, deployment and maintenance of order sets.
The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
Consultant Urological Surgeon Martin Moody FRCS, to present case for safer surgery alongside Henry Schniewind of HAT in Val d'Isère during the medical conference, Doctors Updates.
Zhang and co-principal investigators Sheng Ding, PhD, from The Scripps Research Institute, and Thomas Reh, PhD from the University of Washington, received the highest possible scores for their proposal to investigate the regenerative potential of retinal cells. Their long-term goal is to restore visual function lost through diseases such as macular degeneration and retinitis pigmentosa.
Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.
› Verified 7 days ago